火速出手！最热概念股被警示

Core Viewpoint - Companies YHLO and Ingetech received regulatory warnings from the Shanghai Stock Exchange due to inaccurate and incomplete disclosures regarding their involvement in the "brain-computer interface" sector [1] Group 1: YHLO - YHLO voluntarily disclosed a strategic cooperation framework agreement with Shenzhen Brain Machine Starlink Technology Co., stating collaboration in product development, market promotion, and equity investment [2] - Following regulatory prompting, YHLO issued a supplementary announcement clarifying that Brain Machine Starlink's current research products focus solely on non-invasive technology, with no invasive technology development [3] - The Shanghai Stock Exchange criticized YHLO for inconsistent statements regarding the technology paths of its partner and for failing to adequately disclose risks related to cooperation feasibility and uncertainties [3] Group 2: Ingetech - Ingetech claimed its IPA1299 chip, designed for high-precision measurement of human bioelectric signals, could compete with leading overseas chip products [4] - After regulatory intervention, Ingetech clarified that the IPA1299 chip is co-developed with a subsidiary and is still in the market cultivation phase, with no significant impact on company performance yet [4] - The Shanghai Stock Exchange noted that Ingetech's disclosures did not accurately reflect the product's development status, sales scale, and significant technical differences from international invasive brain-computer interfaces [4] Group 3: Industry Context - Multiple companies, including Xinghuan Technology and Bibeite, have issued risk warnings due to significant stock price fluctuations, emphasizing the need for rational investment decisions [5] - Companies involved in the brain-computer interface sector have highlighted that their products are primarily in the research or market cultivation stages, with a focus on non-invasive routes, contrasting with the invasive methods prevalent internationally [6] - Industry analysts predict that medical applications of brain-computer interfaces may take 3 to 5 years for approval, with consumer-grade devices facing longer development cycles and challenges in user experience and market acceptance [7]